

CMP Therapeutics gains CE mark for Novel Rhinitis product - Atlantic Secret™

London, UK, 6 January 2012 - CMP Therapeutics (CMPT), a health and wellness company developing products for respiratory and gastroenterological diseases, is pleased to announce the successful registration of its lead product, *Atlantic Secret™*, an intranasal spray for rhinitis due to colds, flu and allergy. The active ingredient of *Atlantic Secret™*, is the polysaccharide, β 1-3 N-acetyl glucosamine formulated as a microgel. *Atlantic Secret™* is designed to help prevent and relieve symptoms of rhinitis associated with both nasal infection and allergy. *Atlantic Secret™* sanitizes the nasal cavity and provides a residual barrier on the nasal mucosal surface that acts to inhibit the ingress of micro-organisms (such as cold, flu viruses and moulds), allergens and dust particulates. The product is registered as a medical device class 3 with a CE mark and is approved for sale in Europe. CMP Therapeutics, as the designated manufacturer of the product, was also granted ISO 13485 (medical device) certification. In addition, CMPT has granted and pending worldwide patents to protect the chitin microparticle platform and *Atlantic Secret™*.

Dr Neill Moray Mackenzie, CEO, said: "Registration of a product is the major achievement for any Biotech company, but particularly for a virtual company such as CMPT. This registration enables the Company to sell *Atlantic Secret™* throughout Europe. The European Market for over-the counter, direct to consumer, products for rhinitis is significant and a product with natural origins, such as *Atlantic Secret™*, has great potential. *Atlantic Secret™* is recommended for the prevention and treatment of rhinitis, and the advantage of the novel, proprietary, barrier-forming microgel is that it is likely to prevent a runny nose whatever the cause".

He went on to say "We are currently looking for marketing and distribution partners right now to allow CMPT to expand into Europe and later to the rest of the world".

Contact

Dr Neill Moray Mackenzie
CEO
CMP Therapeutics
Tel: +44 (0)7770 404929
neill.mackenzie@cmptherapeutics.com
www.cmptherapeutics.com

About CMP Therapeutics

CMP Therapeutics Ltd, is an Oxford University, spin-out, company founded in 2004 that develops products for colds, flu, allergy and IBD based on β 1-3 N-acetyl glucosamine (chitin). β 1-3 N-acetyl glucosamine is extracted from natural sources. It is processed into micro-particles (Chitin Micro-Particles or CMP) under GMP manufacturing conditions. CMP is the active component. When administered intranasally it has been shown to be safe in man and effective in models of disease, including viral disease and bacterial diseases of the respiratory tract and allergy. CMP Therapeutics has worldwide patents and patent applications covering the uses and the manufacture of CMP for allergy, viral and bacterial disease, and as a vaccine adjuvant.

CMP Therapeutics is financed by Inventages Venture Capital and BiopacificVentures.

About *Atlantic Secret*TM

*Atlantic Secret*TM is a patented nasal spray product containing a microgel suspension of 0.5% chitin (polysaccharide of *N*-acetylglucosamine) in buffered saline.

*Atlantic Secret*TM is a first-in-class nasal product that confers complete barrier protection against harmful pathogens and airborne irritants. *Atlantic Secret*TM is designed to help prevent and relieve symptoms of rhinitis associated with both nasal infection and allergy. *Atlantic Secret*TM sanitises the nasal cavity and provides a residual barrier on the nasal mucosal surface that acts to inhibit the ingress of micro-organisms (such as cold, flu viruses and moulds), allergens and dust particulates. The irrigation properties of the product also provide cleansing, moisturising and lubrication of the nasal mucosa whilst the buffering action helps to re-balance the pH of the nasal fluid.

*Atlantic Secret*TM is to be used in the winter, during the cold and flu season, or in spring and summer, during the allergy season before symptoms appear. The direction for use is 1 to 2 sprays into each nostril twice a day. The use of the product is to be continued for up to three days after symptoms have subsided. *Atlantic Secret*TM is suitable for adults and children over 12-years. *Atlantic Secret*TM is for nasal use only.

*Atlantic Secret*TM is a CE Marked Class III Medical Device approved for sale in the European Community.

CMP Therapeutics Ltd. is the license holder and designated manufacturer for *Atlantic Secret*TM. CMP Therapeutics Ltd. also holds a certification for ISO 13485.